Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer’s disease pathology

GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease

(2017) Yazhou Li et al.   JOURNAL OF ALZHEIMERS DISEASE

GLP-1 Agonists in Type 1 Diabetes Mellitus

(2016) Kristin M. Janzen et al.   ANNALS OF PHARMACOTHERAPY

Glucagon-Like Peptide-1-Mediated Modulation of Inflammatory Pathways in the Diabetic Brain: Relevance to Alzheimer's Disease

(2016) LiMei Qin et al.   Current Alzheimer Research

The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

(2016) Dilan Athauda et al.   DRUG DISCOVERY TODAY

Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model

(2016) Liqin Qi et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Impairment of biliverdin reductase-A promotes brain insulin resistance in Alzheimer disease: A new paradigm

(2016) Eugenio Barone et al.   FREE RADICAL BIOLOGY AND MEDICINE

In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

(2016) Michael Gejl et al.   Frontiers in Aging Neuroscience

Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice

(2015) Paula L. McClean et al.   BEHAVIOURAL BRAIN RESEARCH

Glucagon-like peptide-1 protects the murine hippocampus against stressors via Akt and ERK1/2 signaling

(2015) Yuta Yoshino et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The Neuroprotective Effect of Liraglutide is Mediated by Glucagon-Like Peptide 1 Receptor-Mediated Activation of cAMP/PKA/CREB Pathway

(2015) Yi Bao et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline

(2015) V. A. Gault et al.   DIABETES OBESITY & METABOLISM

Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats

(2015) Volkan Solmaz et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Sitagliptin attenuated brain damage and cognitive impairment in mice with chronic cerebral hypo-perfusion through suppressing oxidative stress and inflammatory reaction

(2015) Tzu-Hsien Tsai et al.   JOURNAL OF HYPERTENSION

Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Reduces Alzheimer Disease-Associated Tau Hyperphosphorylation in the Hippocampus of Rats With Type 2 Diabetes

(2015) Weijie Xu et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Glucagon-Like Peptide-1 Strengthens the Barrier Integrity in Primary Cultures of Rat Brain Endothelial Cells Under Basal and Hyperglycemia Conditions

(2015) Shuji Fukuda et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Hippocampal insulin resistance and cognitive dysfunction

(2015) Geert Jan Biessels et al.   NATURE REVIEWS NEUROSCIENCE

Modulation of insulin signaling rescues BDNF transport defects independent of tau in amyloid-β oligomer-treated hippocampal neurons

(2015) Oliver Takach et al.   NEUROBIOLOGY OF AGING

A new perspective on the role of the CREB family of transcription factors in memory consolidation via adult hippocampal neurogenesis

(2015) Sylvia Ortega-Martínez   Frontiers in Molecular Neuroscience

Aberrant insulin signaling in Alzheimer's disease: current knowledge

(2015) Gaurav Bedse et al.   Frontiers in Neuroscience

Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain

(2015) Simon C. Cork et al.   Molecular Metabolism

Preservation of the Blood Brain Barrier and Cortical Neuronal Tissue by Liraglutide, a Long Acting Glucagon-Like-1 Analogue, after Experimental Traumatic Brain Injury

(2015) Jakob Hakon et al.   PLoS One

Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease

(2014) Sergio T. Ferreira et al.   Alzheimers & Dementia

The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease

(2014) Konrad Talbot et al.   Alzheimers & Dementia

Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain

(2014) D. Allan Butterfield et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Inflammation, Defective Insulin Signaling, and Mitochondrial Dysfunction as Common Molecular Denominators Connecting Type 2 Diabetes to Alzheimer Disease

(2014) F. G. De Felice et al.   DIABETES

Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight

(2014) Laurie L. Baggio et al.   JOURNAL OF CLINICAL INVESTIGATION

Glucagon-like peptide-1 protects synaptic and learning functions from neuroinflammation in rodents

(2014) Takashi Iwai et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

(2014) Kathleen M Dungan et al.   LANCET

Dementia in the developing world: risk, impact, and prevention

(2014) Emiliano Albanese et al.   NEUROBIOLOGY OF AGING

Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease

(2014) Paula L. McClean et al.   NEUROPHARMACOLOGY

Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice

(2014) Rachael Lennox et al.   NEUROPHARMACOLOGY

Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism

(2014) Nadia M. Krasner et al.   PLoS One

Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function

(2013) Cassandra Koole et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Geniposide Ameliorates Learning Memory Deficits, Reduces Tau Phosphorylation and Decreases Apoptosis via GSK3β Pathway in Streptozotocin-Induced Alzheimer Rat Model

(2013) Chong Gao et al.   BRAIN PATHOLOGY

TNF-α Mediates PKR-Dependent Memory Impairment and Brain IRS-1 Inhibition Induced by Alzheimer’s β-Amyloid Oligomers in Mice and Monkeys

(2013) Mychael V. Lourenco et al.   Cell Metabolism

The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant?

(2013) Stefan Trapp et al.   CURRENT OPINION IN PHARMACOLOGY

History of Medically Treated Diabetes and Risk of Alzheimer Disease in a Nationwide Case-Control Study

(2013) A.-M. Tolppanen et al.   DIABETES CARE

Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases

(2013) Christian Hölscher   JOURNAL OF ENDOCRINOLOGY

DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats

(2013) Hiranya Pintana et al.   JOURNAL OF ENDOCRINOLOGY

Saxagliptin: A dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease

(2013) Jayasankar Kosaraju et al.   NEUROPHARMACOLOGY

Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease

(2013) Paula L. McClean et al.   NEUROPHARMACOLOGY

Role of central glucagon-like peptide-1 in stress regulation

(2013) Sriparna Ghosal et al.   PHYSIOLOGY & BEHAVIOR

Chronic Treatment with the GLP1 Analogue Liraglutide Increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model

(2013) Vadivel Parthsarathy et al.   PLoS One

Releasing the brake: restoring fast axonal transport in neurodegenerative disorders

(2013) Maria-Victoria Hinckelmann et al.   TRENDS IN CELL BIOLOGY

Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals

(2013) M Bomba et al.   Cell Death & Disease

Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions

(2013) Geert Jan Biessels et al.   Lancet Diabetes & Endocrinology

The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells

(2012) Aya Shiraki et al.   ATHEROSCLEROSIS

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

(2012) Kerry Hunter et al.   BMC NEUROSCIENCE

DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption

(2012) Noppamas Pipatpiboon et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain

(2012) Vadivel Parthsarathy et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice

(2012) David Tweedie et al.   EXPERIMENTAL NEUROLOGY

Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies

(2012) G. Cheng et al.   INTERNAL MEDICINE JOURNAL

Liraglutide, a Long-Acting GLP-1 Mimetic, and its Metabolite Attenuate Inflammation after Intracerebral Hemorrhage

(2012) Jack Hou et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers

(2012) Theresa R. Bomfim et al.   JOURNAL OF CLINICAL INVESTIGATION

Neuroprotective actions of Glucagon-like peptide-1 in differentiated human neuroprogenitor cells

(2012) Kalpana Velmurugan et al.   JOURNAL OF NEUROCHEMISTRY

Glucagon-Like Peptide-1 Cleavage Product GLP-1(9-36) Amide Rescues Synaptic Plasticity and Memory Deficits in Alzheimer's Disease Model Mice

(2012) T. Ma et al.   JOURNAL OF NEUROSCIENCE

Insulin in the Brain: Sources, Localization and Functions

(2012) Rasoul Ghasemi et al.   MOLECULAR NEUROBIOLOGY

Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures

(2012) Dong-Hou Kim et al.   NEUROBIOLOGY OF DISEASE

The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid-β Plaque and Glial Pathology in a Mouse Model of Alzheimer’s Disease

(2012) Caitriona M. Long-Smith et al.   NEUROMOLECULAR MEDICINE

Axonal transport and neurodegenerative disease: Can we see the elephant?

(2012) Lawrence S.B. Goldstein   PROGRESS IN NEUROBIOLOGY

Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer’s disease by exendin-4

(2011) Song Chen et al.   AGE

Snapin Mediates Incretin Action and Augments Glucose-Dependent Insulin Secretion

(2011) Woo-Jin Song et al.   Cell Metabolism

Brain Energy Metabolism: Focus on Astrocyte-Neuron Metabolic Cooperation

(2011) Mireille Bélanger et al.   Cell Metabolism

Neuroprotective properties of GLP-1: theoretical and practical applications

(2011) Jens Juul Holst et al.   CURRENT MEDICAL RESEARCH AND OPINION

(Val8) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains

(2011) Lin Li et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Second Extracellular Loop of Human Glucagon-like Peptide-1 Receptor (GLP-1R) Has a Critical Role in GLP-1 Peptide Binding and Receptor Activation

(2011) Cassandra Koole et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

(2011) P. L. McClean et al.   JOURNAL OF NEUROSCIENCE

Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

(2011) A. Hamilton et al.   JOURNAL OF NEUROSCIENCE RESEARCH

GLP-1 and energy balance: an integrated model of short-term and long-term control

(2011) Jason G. Barrera et al.   Nature Reviews Endocrinology

Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and β cell preservation

(2011) Daisuke Yabe et al.   PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY

GLP-1-derived nonapeptide GLP-1(28–36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes

(2011) Eva Tomas et al.   REGULATORY PEPTIDES

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications

(2010) Michael A. Nauck   AMERICAN JOURNAL OF MEDICINE

Glucagon-like peptide 1 and the brain: Central actions–central sources?

(2010) Stefan Trapp et al.   AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL

Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model

(2010) Paola Luciani et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Building Genetic Scores to Predict Risk of Complex Diseases in Humans: Is It Possible?

(2010) S. Liu et al.   DIABETES

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

(2010) C. F. Deacon   DIABETES OBESITY & METABOLISM

The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test

(2010) Ruben Isacson et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Serotonin syndrome in an orthopaedic patient secondary to linezolid therapy for MRSA infection

(2010) M. McClean et al.   IRISH JOURNAL OF MEDICAL SCIENCE

Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice

(2010) Simon Gengler et al.   NEUROBIOLOGY OF AGING

Insulin metabolism and the risk of Alzheimer disease: The Rotterdam Study

(2010) E. M. C. Schrijvers et al.   NEUROLOGY

Val8-glucagon-like peptide-1 protects against Aβ1–40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats

(2010) X.H. Wang et al.   NEUROSCIENCE

Chronic treatment of exendin-4 affects cell proliferation and neuroblast differentiation in the adult mouse hippocampal dentate gyrus

(2010) Hua Li et al.   NEUROSCIENCE LETTERS

Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides

(2010) Niels Vrang et al.   PROGRESS IN NEUROBIOLOGY

Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease

(2009) Talib Abbas et al.   BEHAVIOURAL BRAIN RESEARCH

Meta-Analysis of Alzheimer's Disease Risk with Obesity, Diabetes, and Related Disorders

(2009) Louis A. Profenno et al.   BIOLOGICAL PSYCHIATRY

Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats

(2009) Holger Fuchs et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections

(2009) A. Fura et al.   DRUG METABOLISM AND DISPOSITION

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease

(2009) Paula L. McClean et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice

(2009) Michele D’Amico et al.   EXPERIMENTAL GERONTOLOGY

Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons

(2009) Denise D. Belsham et al.   FASEB JOURNAL

Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system

(2009) Alison Hamilton et al.   NEUROREPORT

Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway

(2009) R. Kimura et al.   NEUROSCIENCE

Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers

(2009) Fernanda G. De Felice et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes

(2008) J.-F. Gautier et al.   DIABETES & METABOLISM

GLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival

(2008) J. Buteau   DIABETES & METABOLISM

Low, but Physiological, Concentration of GLP-1 Stimulates Insulin Secretion Independent of the cAMP-Dependent Protein Kinase Pathway

(2008) Makoto Shigeto et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Nutritional regulation of glucagon-like peptide-1 secretion

(2008) Gwen Tolhurst et al.   JOURNAL OF PHYSIOLOGY-LONDON

New roles for insulin-like hormones in neuronal signalling and protection: New hopes for novel treatments of Alzheimer’s disease?

(2008) Christian Hölscher et al.   NEUROBIOLOGY OF AGING

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease

(2007) Göran Bertilsson et al.   JOURNAL OF NEUROSCIENCE RESEARCH